GlassScriptPhysician profile
Tahir Haytoglu
NPI 1932609054
$14,010.31
in general payments reported to CMS, 2019-2025
54 companies · $3,631 in 2025
The $3,631 reported for 2025 was more than what 85% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $759 · 2021: $525 · 2022: $2,513 · 2023: $3,387 · 2024: $3,195 · 2025: $3,631.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $10K · Education: $76.90.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,135.68 |
| Education | $76.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $1,412.60 | 2019-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Dexcom, INC. | $1,363.48 | 2021-2025 | Dexcom G6 Transmitter |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,226.10 | 2019-2025 | Jardiance, Synjardy |
| Amgen INC. | $1,104.07 | 2019-2025 | Repatha, Tepezza, Repatha |
| Novo Nordisk INC | $943.98 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $704.69 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Medtronic, INC. | $589.39 | 2021-2025 | Minimed 780g, Minimed 770g |
| Novartis Pharmaceuticals Corporation | $532.50 | 2023-2025 | |
| Sanofi-Aventis U.S. LLC | $488.03 | 2019-2025 | |
| Insulet Corporation | $487.60 | 2019-2025 | Omnipod |
| Recordati_rare_diseases_inc. | $472.60 | 2023-2025 | Isturisa, Signifor Lar |
| Xeris Pharmaceuticals, INC. | $362.27 | 2021-2025 | Recorlev, Gvoke Hypopen |
| Bigfoot Biomedical INC | $361.30 | 2022 | |
| Horizon Therapeutics Plc | $360.75 | 2021-2023 | Tepezza |
| Ascendis Pharma Endocrinology INC | $277.50 | 2025 | Yorvipath |
Show all 54 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tandem Diabetes Care, INC. | $271.73 | 2019-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Kyowa Kirin, INC. | $248.00 | 2023-2025 | Crysvita |
| Madrigal Pharmaceuticals | $240.73 | 2024-2025 | Rezdiffra, Resmetirom |
| Bayer Healthcare Pharmaceuticals INC. | $229.43 | 2023-2025 | |
| Alexion Pharmaceuticals, INC. | $221.40 | 2019-2024 | Strensiq |
| Abbvie INC. | $206.97 | 2019-2025 | |
| Beta Bionics, INC. | $198.51 | 2024-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Corcept Therapeutics | $190.49 | 2022-2025 | Korlym |
| Antares Pharma, INC. | $186.54 | 2022-2023 | Nocdurna, Xyosted, Tlando |
| Ascensia Diabetes Care US INC. | $162.01 | 2021-2025 | |
| Radius Health, INC. | $110.68 | 2022-2025 | Tymlos |
| Pfizer INC. | $103.97 | 2022-2024 | |
| Astrazeneca Pharmaceuticals LP | $103.76 | 2019-2022 | |
| Mannkind Corporation | $91.19 | 2021-2025 | Afrezza |
| Merck Sharp & Dohme LLC | $54.73 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $53.11 | 2019 | |
| Halozyme INC | $52.39 | 2023 | |
| Embecta Corp. | $51.18 | 2023-2024 | Bd Nano 2nd Gen Pen Needle |
| Valeritas, INC. | $49.66 | 2019 | |
| Tolmar, INC. | $48.97 | 2023-2025 | Jatenzo |
| Ibsa Pharma INC. | $36.93 | 2021-2022 | |
| Medtronic Minimed, INC. | $36.73 | 2019 | |
| Acerus Pharmaceuticals Corporation | $35.63 | 2022 | |
| Alvogen INC | $30.95 | 2023 | Teriparatide |
| Astellas Pharma US INC | $30.87 | 2024 | Veozah |
| Neurocrine Biosciences, INC. | $26.38 | 2025 | |
| Grt US Holding, INC. | $25.78 | 2022 | |
| Currax Pharmaceuticals LLC | $25.00 | 2023 | Nexletol |
| Alfasigma USA, INC. | $24.67 | 2022 | |
| Cequr Corporation | $22.78 | 2023-2024 | Cequr Simplicity |
| Zealand Pharma US, INC. | $22.41 | 2022 | |
| Esperion Therapeutics, INC. | $21.83 | 2021 | |
| Amryt Pharma Holdings LTD | $19.57 | 2022 | |
| Nevro Corp. | $16.91 | 2022 | |
| Amphastar Pharmaceuticals, INC. | $16.74 | 2025 | |
| Amarin Pharma, INC. | $14.43 | 2021 | |
| Echosens North America, INC. | $14.25 | 2023 | Fibroscan |
| Lifescan, INC. | $13.36 | 2022 | |
| Clarus Therapeutics INC. | $12.78 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tahir Haytoglu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.